Home>
US Stocks>
Halozyme Therapeutics

Halozyme Therapeutics share price today

(HALO)

Halozyme Therapeutics share price is $46.96 & ₹3,990.47 as on 21 Dec 2024, 2.30 'hrs' IST

$46.96

▲

-0.36

(-0.76%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Halozyme Therapeutics share price in Dollar and Rupees. Guide to invest in Halozyme Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Halozyme Therapeutics. Get details on the Indian mutual funds that are investing in Halozyme Therapeutics. Get Analyst recommendations and forecasts along with all the Halozyme Therapeutics's financials.

Halozyme Therapeutics share price movements

Today's Low: $46.92
Today's High: $48.19
$46.96
0.09%
Downside
Day's Volatility :2.63%
Upside
2.54%
52 Weeks Low: $33.15
52 Weeks High: $65.53
$46.96
29.41%
Downside
52 Weeks Volatility :49.41%
Upside
28.34%

Halozyme Therapeutics Returns

Period	Halozyme Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-19.15%	-12.2%	0.0%
6 Months	-9.1%	-6.9%	0.0%
1 Year	27.38%	2.7%	0.0%
3 Years	19.71%	-0.2%	-17.3%

Halozyme Therapeutics Key Statistics

in dollars & INR

Previous Close	$47.32
Open	$47.03
Today's High	$48.185
Today's Low	$46.92
Market Capitalization	$6.0B
Today's Volume	$1.7M
52 Week High	$65.5327
52 Week Low	$33.15
Revenue TTM	$947.4M
EBITDA	$553.0M
Earnings Per Share (EPS)	$3.02
PE Ratio	15.51
Profit Margin	41.43%
Quarterly Earnings Growth YOY	0.72%
Return On Equity TTM	111.83%

How to invest in Halozyme Therapeutics from India?

It is very easy for Indian residents to invest directly in Halozyme Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Halozyme Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Halozyme Therapeutics or HALO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Halozyme Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Halozyme Therapeutics shares which would translate to 0.018 fractional shares of Halozyme Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Halozyme Therapeutics, in just a few clicks!

Returns in Halozyme Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Halozyme Therapeutics investment value today

Current value as on today

₹1,28,502

Returns

₹28,502

(+28.5%)

Returns from Halozyme Therapeutics Stock

₹26,406 (+26.41%)

Dollar Returns

₹2,095 (+2.1%)

Indian investors sentiment towards Halozyme Therapeutics

-19%

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Halozyme Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 21, 2024. -19% less investors are searching Halozyme Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Halozyme Therapeutics

BlackRock Inc
13.85%
Vanguard Group Inc
10.14%
State Street Corp
5.21%
Snyder Capital Management LP
3.19%
AllianceBernstein L.P.
2.68%
Artisan Partners Limited Partnership
2.46%

Analyst Recommendation on Halozyme Therapeutics

Buy

82%Buy

17%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Halozyme Therapeutics(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Halozyme Therapeutics

What analysts predicted

Upside of 36.29%

Current:

$46.96

Target:

$64.00

Insights on Halozyme Therapeutics

Price Movement
In the last 7 days, HALO stock has moved down by -1.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 195.87M → 290.08M (in $), with an average increase of 17.8% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 76.82M → 137.01M (in $), with an average increase of 24.8% per quarter
HALO vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 33.4% return, outperforming this stock by 3.3%
Price to Sales
ForHALO every $1 of sales, investors are willing to pay $6.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.5 for every $1 of sales.

Halozyme Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$151.9M	↓ 52.04%
Net Income	$-80.3M	↓ 227.57%
Net Profit Margin	-52.9%	↓ 72.79%

	FY19	Y/Y Change
Revenue	$196.0M	↑ 29.06%
Net Income	$-72.2M	↓ 10.07%
Net Profit Margin	-36.86%	↑ 16.04%

	FY20	Y/Y Change
Revenue	$267.6M	↑ 36.53%
Net Income	$129.1M	↓ 278.69%
Net Profit Margin	48.24%	↑ 85.1%

	FY21	Y/Y Change
Revenue	$443.3M	↑ 65.67%
Net Income	$402.7M	↑ 211.97%
Net Profit Margin	90.84%	↑ 42.6%

	FY22	Y/Y Change
Revenue	$660.1M	↑ 48.91%
Net Income	$202.1M	↓ 49.81%
Net Profit Margin	30.62%	↓ 60.22%

	FY23	Y/Y Change
Revenue	$829.3M	↑ 25.62%
Net Income	$281.6M	↑ 39.31%
Net Profit Margin	33.96%	↑ 3.34%

	Q2 FY23	Q/Q Change
Revenue	$221.0M	↑ 36.32%
Net Income	$74.8M	↑ 88.7%
Net Profit Margin	33.82%	↑ 9.39%

	Q3 FY23	Q/Q Change
Revenue	$216.0M	↓ 2.26%
Net Income	$81.8M	↑ 9.48%
Net Profit Margin	37.88%	↑ 4.06%

	Q4 FY23	Q/Q Change
Revenue	$230.0M	↑ 6.48%
Net Income	$85.4M	↑ 4.34%
Net Profit Margin	37.12%	↓ 0.76%

	Q1 FY24	Q/Q Change
Revenue	$195.9M	↓ 14.85%
Net Income	$76.8M	↓ 10.03%
Net Profit Margin	39.22%	↑ 2.1%

	Q2 FY24	Q/Q Change
Revenue	$231.4M	↑ 18.11%
Net Income	$93.2M	↑ 21.38%
Net Profit Margin	40.3%	↑ 1.08%

	Q3 FY24	Q/Q Change
Revenue	$290.1M	↑ 25.39%
Net Income	$137.0M	↑ 46.94%
Net Profit Margin	47.23%	↑ 6.93%

	FY18	Y/Y Change
Profit	$141.7M	↓ 50.35%

	FY19	Y/Y Change
Profit	$150.4M	↑ 6.15%

	FY20	Y/Y Change
Profit	$224.2M	↑ 49.04%

	FY21	Y/Y Change
Profit	$361.9M	↑ 61.4%

	FY22	Y/Y Change
Profit	$520.8M	↑ 43.91%

	FY23	Y/Y Change
Profit	$636.9M	↑ 22.29%

	Q2 FY23	Q/Q Change
Profit	$171.0M	↑ 34.65%

	Q3 FY23	Q/Q Change
Profit	$161.2M	↓ 5.71%

	Q4 FY23	Q/Q Change
Profit	$177.7M	↑ 10.25%

	Q1 FY24	Q/Q Change
Profit	$149.8M	↓ 15.73%

	Q2 FY24	Q/Q Change
Profit	$174.0M	↑ 16.15%

	Q3 FY24	Q/Q Change
Profit	$240.7M	↑ 38.32%

	FY18	Y/Y Change
Operating Cash Flow	$-49.5M	↓ 136.93%
Investing Cash Flow	$2.5M	↓ 101.52%
Financing Cash Flow	$-63.8M	↓ 148.46%

	FY19	Y/Y Change
Operating Cash Flow	$-85.4M	↑ 72.57%
Investing Cash Flow	$-5.5M	↓ 322.58%
Financing Cash Flow	$153.2M	↓ 340.16%

	FY20	Y/Y Change
Operating Cash Flow	$55.5M	↓ 164.92%
Investing Cash Flow	$78.4M	↓ 1512.04%
Financing Cash Flow	$-106.3M	↓ 169.37%

	FY21	Y/Y Change
Operating Cash Flow	$299.4M	↑ 439.98%
Investing Cash Flow	$-406.3M	↓ 618.53%
Financing Cash Flow	$77.9M	↓ 173.26%

	FY22	Y/Y Change
Operating Cash Flow	$240.1M	↓ 19.81%
Investing Cash Flow	$-487.0M	↑ 19.87%
Financing Cash Flow	$362.4M	↑ 365.38%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$66.8M	↓ 23.14%
Investing Cash Flow	$55.0M	↓ 191.41%
Financing Cash Flow	$2.4M	↓ 101.49%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$132.4M	↑ 98.1%
Investing Cash Flow	$-83.5M	↓ 251.74%
Financing Cash Flow	$4.1M	↑ 67.66%

Halozyme Therapeutics Technicals Summary

Sell

Neutral

Buy

Halozyme Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Halozyme Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Halozyme Therapeutics, Inc.	3.41%	-9.1%	27.38%	19.71%	156.06%
Regeneron Pharmaceuticals, Inc.	-4.72%	-33.43%	-16.35%	14.7%	89.27%
Biontech Se	9.01%	28.55%	5.71%	-57.13%	220.59%
Alnylam Pharmaceuticals, Inc.	-3.99%	7.16%	25.05%	27.48%	103.59%
Vertex Pharmaceuticals Incorporated	-12.1%	-16.49%	-2.12%	78.05%	80.31%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Halozyme Therapeutics, Inc.	15.51	15.51	-2.5	4.13	1.12	0.15	NA	3.56
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.05	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Halozyme Therapeutics, Inc.	Buy	$6.0B	156.06%	15.51	41.43%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	89.27%	17.67	33.61%
Biontech Se	Buy	$26.8B	220.59%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.7B	103.59%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$115.2B	80.31%	32.84	-4.51%

About Halozyme Therapeutics

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies

Organization	Halozyme Therapeutics
Employees	373
CEO	Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Industry	Health Technology

Management People of Halozyme Therapeutics

Name	Title
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.	President, CEO & Director
Ms. Nicole LaBrosse CPA	Senior VP & CFO
Dr. Michael J. LaBarre Ph.D.	Senior VP & CTO
Mr. Mark Snyder Esq.	Senior VP & Chief Legal Officer
Ms. Cortney Caudill M.B.A.	Chief Operations Officer
Ms. Tram Bui	Head of Investor Relations & Corporate Communications
Ms. Amy Marinne Fox	Chief Human Resources Officer
Mr. Gary Grote	Chief Commercial Officer
Dr. Christopher Wahl M.B.A., M.D.	Chief Business Officer
Dr. Charles P. Theuer M.D., Ph.D.	Chief Medical Officer

Important FAQs about investing in Halozyme Therapeutics from India :

What is Halozyme Therapeutics share price today?

Halozyme Therapeutics share price today stands at $46.96, Open: $47.03 ; Previous Close: $47.32 ; High: $48.19 ; Low: $46.92 ; 52 Week High: $65.53 ; 52 Week Low: $33.15. The stock opens at $47.03, after a previous close of $47.32. The stock reached a daily high of $48.19 and a low of $46.92, with a 52-week high of $65.53 and a 52-week low of $33.15.

Can Indians buy Halozyme Therapeutics shares?

Yes, Indians can invest in the Halozyme Therapeutics (HALO) from India.

With INDmoney, you can buy Halozyme Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Halozyme Therapeutics at zero transaction cost.

How can I buy Halozyme Therapeutics shares from India?

It is very easy to buy Halozyme Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Halozyme Therapeutics be purchased?

Yes, you can buy fractional shares of Halozyme Therapeutics with INDmoney app.

What are the documents required to start investing in Halozyme Therapeutics stocks?

To start investing in Halozyme Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.